I think that in the premenopausal population there are different issues that should be covered. We have a population of very low risk that even tamoxifen was considered the standard of care. Even though we have another population that is the in-situ carcinoma where tamoxifen is standard of care in premenopausal patients. So for these two populations, we do not consider ovarian suppression...
I think that in the premenopausal population there are different issues that should be covered. We have a population of very low risk that even tamoxifen was considered the standard of care. Even though we have another population that is the in-situ carcinoma where tamoxifen is standard of care in premenopausal patients. So for these two populations, we do not consider ovarian suppression. But tamoxifen continues to have some symptoms related to the toxicity and also the potential to find a drug that could be superior in preventing both in-situ and early stages for preventing second breast cancer. So I think that for these populations, I think that this new serum cells product could have an opportunity. The second population are the ones at a higher risk, the ones that will usually combine ovarian suppression with aromatase inhibitor or even tamoxifen. And in these populations, perhaps not the whole duration of the treatment but we know that probably five years of ovarian suppression with aromatase inhibitors is a very tough regimen so we can start to imagine that we can reduce the intensity of ovarian suppression by just giving two years or even finding a drug that could replace completely this ovarian suppression that would be of great help even for this high-risk patient. So I think that it goes in both ways, particularly when thinking on the toxicity of this treatment when combining it with chemotherapy for six months for high-risk patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
